A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

Shares in Ozempic maker Novo Nordisk tumbled after an experimental anti-obesity shot fell short of expectations. The shares fell more than 20% in Copenhagen, closing at their lowest since August 2023.

The weight loss and diabetes drugs Wegovy and Ozempic have transformed the fortunes of Novo Nordisk, leading it more than triple in value in the past five years. Barclays had previously modelled $ ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...

Novo Nordisk CEO Lars Fruergaard Joergensen in December during a presentation of a new production site. The company's latest attempt at a weight loss drug, CagriSema, matched the bar set by a ...

According to its website, Novo Nordisk was founded in 1923 in Copenhagen, Denmark’s capital city. It is best known for manufacturing diabetes medications, including Ozempic and Wegovy.

According to its website, Novo Nordisk was founded in 1923 in Copenhagen, Denmark’s capital city. It is best known for manufacturing diabetes medications, including Ozempic and Wegovy. Ozempic is used ...

Shares in Novo Nordisk have fallen by more than a quarter after the Ozempic maker revealed a set ... bond yields have surged higher - with 30-year gilt coupons close to their highest level since ...